drugset / Trial / NCT05901584
Cadonilimab (AK104) With or Without CT as 2rd Line Treatment for ES-SCLC
Phase 2
Unknown
30 enrolled
Second Affiliated Hospital of Zunyi Medical University
Guizhou Provincial People's Hospital · collabGuizhou Tongren People's Hospital · collabThe First People's Hospital of Zunyi · collabThe People"s Hospital of Xingyi · collabThe Second Affiliated Hospital of Guizhou Medical University · collab
NaSingle-groupOpen-labelHealth-services research
Summary
This study is a phase II clinical study of Cadonilimab (AK104) combined with or without chemotherapy in the treatment of PD-1 inhibitor-resistant extensive stage small cell lung cancer
Timeline
- Start
- 2023-01-01
- Primary completion
- 2024-12
- Completion
- 2024-12
Publications
- Background Pang X, Huang Z, Zhong T, Zhang P, Wang ZM, Xia M, Li B. Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity. MAbs. 2023 Jan-Dec;15(1):2180794. doi: 10.1080/19420862.2023.2180794.
- Chen C, Chen M, Bai Y, Li Y, Peng J, Yao B, Feng J, Zhou JG, Ma H. A Single-Arm Multi-Center Phase II Clinical Trial of Cadonilimab (anti-PD-1/CTLA-4) in Combination with or without Conventional Second-Line Treatment for Patients with Extensive Stage Small Cell Lung Cancer. Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241249690. doi: 10.1177/15330338241249690.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cadonilimab | Monoclonal antibody | 10 mg/kg | — |
Indications
No indication recorded.